Biocon Limited, an innovation-led global biopharmaceutical company, has successfully launched its Glucagon-like Peptide-1 (GLP-1) drug, Liraglutide, in the Netherlands.
The launch, which took place on December 15, 2025, marks a significant strategic entry, as the Netherlands is the first country in the European Union where the company will directly launch Liraglutide under its own brand.
The introduction follows approval granted earlier this year by the Medicines Evaluation Board (MEB), Netherlands.
Biocon is marketing the drug-device combination for two distinct chronic conditions via its distribution partner, Pharmamedic B.V.. For the treatment of diabetes, the product will be marketed under the brand name Diavorin® (a generic version of Victoza® or gVictoza®), and for chronic weight management, it will be sold as Vobexoryn® (a generic version of Saxenda® or gSaxenda®).
Liraglutide is a synthetic analog of the GLP-1 peptide and is administered as a once-daily injection. Medications based on GLP-1 are physiological hormones that help in lowering blood sugar levels and promoting weight loss.
They function by augmenting insulin and inhibiting glucagon secretion, thereby controlling meal-related glycemic excursions. Additionally, GLP-1 inhibits gastric emptying and food intake, which maximizes nutrient absorption while limiting weight gain.
Siddharth Mittal, Chief Executive Officer and Managing Director of Biocon Limited, commented that the launch signifies a major milestone in expanding Biocon’s GLP-1 portfolio across key global markets, stressing the strategic importance of peptide-based therapies within their portfolio. Mr. Mittal stated that the ability to launch Diavorin® and Vobexoryn® under the company’s own brand in Europe reflects their scientific and manufacturing excellence.
He further highlighted that Biocon is uniquely positioned to deliver high-quality, affordable metabolic treatments at scale, aiding in the mission to serve patients and support more sustainable healthcare systems.
The distribution partner, Pharmamedic B.V., is a leading supplier of generic drugs in the Dutch market, focusing on unique and specialized products within niche segments. They serve as a bridge between international manufacturers and Dutch healthcare providers, utilizing extensive knowledge of the local market.
The corporate filing regarding this Press Release was signed by Rajesh U. Shanoy. The information was filed to the BSE Limited and the National Stock Exchange of India Limited under the subject “Press Release”.
Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.
